Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Parque Tecnológico de La Salud (PTS), Granada, Spain.
Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (IPBLN-CSIC), Parque Tecnológico de La Salud (PTS), Granada, Spain.
J Autoimmun. 2015 Nov;64:53-65. doi: 10.1016/j.jaut.2015.07.005. Epub 2015 Jul 23.
Systemic sclerosis (SSc) is a clinically heterogeneous connective tissue disorder of complex etiology. The development of large-scale genetic studies, such as genome-wide association studies (GWASs) or the Immunochip platform, has achieved remarkable progress in the knowledge of the genetic background of SSc. Herein, we provide an updated picture SSc genetic factors, offering an insight into their role in pathogenic mechanisms that characterize the disease. We review the most recent findings in the HLA region and the well-established non-HLA loci. Up to 18 non-HLA risk factors fulfilled the selected criteria and they were classified according to their role in the innate or adaptive immune response, in apoptosis, autophagy or fibrosis. Additionally, SSc heritability has remained as a controversial question since twin studies provided low SSc heritability estimates. However, we have recalculated the lower bond of narrow sense SSc heritability using GWAS data. Remarkably, our results suggest a greater influence of genetics on SSc than previously reported. Furthermore, we also offer a functional classification of SSc-associated SNPs and their proxies, based on annotated data, to provide clues for the identification of causal variants in these loci. Finally, we explore the genetic overlap between SSc and other autoimmune diseases (ADs). The vast majority of SSc risk loci are shared with at least one additional AD, being the overlap between SSc and systemic lupus erythematous the largest. Nevertheless, we found that an important portion of SSc risk factors are also common to rheumatoid arthritis or primary biliary cirrhosis. Considering all these evidences, we are confident that future research will be successful in understanding the relevant altered pathways in SSc and in identifying new biomarkers and therapeutic targets for the disease.
系统性硬化症(SSc)是一种临床异质性的复杂病因结缔组织疾病。大规模遗传研究(如全基因组关联研究(GWAS)或免疫芯片平台)的发展在 SSc 的遗传背景知识方面取得了显著进展。在此,我们提供了 SSc 遗传因素的最新图片,深入了解它们在疾病特征的发病机制中的作用。我们综述了 HLA 区域和已确立的非 HLA 基因座的最新发现。多达 18 个非 HLA 风险因素符合选定的标准,并根据它们在先天或适应性免疫反应、细胞凋亡、自噬或纤维化中的作用进行分类。此外,自从双胞胎研究提供了低 SSc 遗传性估计以来,SSc 的遗传性一直是一个有争议的问题。然而,我们使用 GWAS 数据重新计算了狭义 SSc 遗传性的下限。值得注意的是,我们的结果表明遗传对 SSc 的影响比以前报道的更大。此外,我们还根据注释数据对 SSc 相关 SNP 及其近缘物进行了功能分类,为这些基因座中因果变异的鉴定提供线索。最后,我们探讨了 SSc 与其他自身免疫性疾病(AD)之间的遗传重叠。绝大多数 SSc 风险基因座与至少一种其他 AD 共享,SSc 与系统性红斑狼疮的重叠最大。然而,我们发现 SSc 风险因素的很大一部分也与类风湿关节炎或原发性胆汁性肝硬化共同存在。考虑到所有这些证据,我们有信心,未来的研究将成功地理解 SSc 中相关改变的途径,并为该疾病确定新的生物标志物和治疗靶点。